Adrabetadex clinical trials
Also written VTS-270.
How each study uses adrabetadex is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Mandos LLC (3) · Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company (2) · Washington University School of Medicine (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · ZyVersa Therapeutics, Inc. (1)
Studies
Open first, then newest update. How each study uses adrabetadex is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type CCompletedPhase 1/2Washington University School of MedicineNCT03471143Written as VTS-270
- P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney DiseaseWithdrawnPhase 2ZyVersa Therapeutics, Inc.NCT06489340Written as 2HPβCD
- Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous SystemTerminatedPhase 3Mandos LLCNCT03643562Written as Adrabetadex
- Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1TerminatedPhase 2/3Mandos LLCNCT03879655Written as VTS-270
- Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) DiseaseTerminatedPhase 2/3Mandos LLCNCT04958642Written as Adrabetadex
- Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1TerminatedPhase 1/2Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT03887533Written as VTS-270
- Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 DiseaseCompletedPhase 1Vtesse, LLC, a Mallinckrodt Pharmaceuticals CompanyNCT01747135Written as VTS-270
- Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) DiseaseWithdrawnPhase 2Vtesse, LLC, a Mallinckrodt Pharmaceuticals CompanyNCT03687476Written as VTS-270
As the comparator · 1 — what is tested is compared with adrabetadex
Codes
What other systems call adrabetadex · ClinicalTrials.gg INT015730
- UNII (FDA) 8W6Q67R6NXADRABETADEXOne source FDA
- RxNorm 2105627One source FDA
- NCI Thesaurus C175052AdrabetadexOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8W6Q67R6NX | ADRABETADEX | One source FDA |
| RxNorm | 2105627 | — | One source FDA |
| NCI Thesaurus | C175052 | Adrabetadex | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.